Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 38 clinical trials
Targeted Dose-Escalated Intravenous Busulfan and Bolus Etoposide as Preparative Therapy for Patients With Acute Myeloid Leukemia Undergoing Autologous Stem Cell Transplantation

The study hypothesis is that higher dose intravenous busulfan can be delivered safely to AML patients undergoing autologous transplantation. If this hypothesis is true the investigators

ara-c
cytarabine
cell transplantation
busulfan
  • 19 views
  • 07 Nov, 2020
  • 1 location
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)

platelet count
tumor burden
rituximab
bendamustine
neutrophil count
  • 37 views
  • 26 Mar, 2021
  • 37 locations
Administration of Adipose-derived Stem Cells (ASC) in Patient With Critical Limb Ischemia

clinical trial is to confirm the efficacy autologous transplantation of adipose tissue derived mesenchymal cells in patients with critical limb ischemia with poor options or no option for revascularization

  • 0 views
  • 25 Jan, 2021
  • 2 locations
Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma

inferior in patients with multiply relapsed or chemo-refractory disease with only 0-20% of patients achieving long-term disease control with autologous transplantation. Thus a large proportion of

zevalin
hodgkin's disease
transplant conditioning
rituximab
aggressive non-hodgkin's lymphoma
  • 26 views
  • 07 Nov, 2020
  • 1 location
Prevention of Oral Mucositis Using Photobiomodulation Therapy

Oral mucositis is a significant and common toxicity experienced by patients who receive high-dose chemotherapy as a preparatory regimen for a hematopoietic cell transplant (HCT). Furthermore, oral mucositis has been reported as the single most debilitating side effect reported by patients undergoing HCT. The incidence of HCT mucositis among adults …

mucositis
high dose chemotherapy
  • 3 views
  • 17 Feb, 2021
  • 1 location
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd) Then Maintenance With Ixazomib (IXA) or IXA-Dara

by the bortezomib dosing schedule. Patients enrolled in the VTd arm will receive: 4 cycles of bortezomib-thalidomide-dexamethasone induction, followed by autologous transplantation and 2

immunohistochemistry
vasectomy
platelet count
bone marrow procedure
velcade
  • 60 views
  • 24 Jan, 2021
  • 5 locations
Treatment of COPD by Autologous Transplantation of Bronchial Basal Cells

Bronchial basal cells are proved to be able to regenerate lung structures to repair the injured lung. In COPD patients, bronchus structures are injured and cannot be repaired, which may result in the failure of pulmonary function rescue clinically.In our research, autologous bronchial basal cells will be transplanted into lung …

dyspnea
pulmonary function test
cough
  • 22 views
  • 21 Jan, 2021
  • 1 location
High Dose Chemotherapy and Autologous Transplant for Neuroblastoma

This is a standard of care document, outlining the therapy for children with high risk neuroblastoma who are not eligible for Children's Oncology Group (COG) studies.

stem cell transplantation
carboplatin
granulocyte colony stimulating factor
etoposide
monoclonal antibody ch14.18
  • 5 views
  • 19 Mar, 2021
  • 1 location
MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

This research study tests a new medicine for mobilizing stem cells so they can be collected and used for autologous stem cell transplant for treatment of multiple myeloma. MGTA-145, the new medicine, will be given with plerixafor.

  • 0 views
  • 27 Jan, 2021
  • 1 location
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration

Background Age-related macular degeneration is a common eye disease in people over 50. The "dry" form of the disease can worsen into geographic atrophy, causing blind spots. Researchers want to learn if replacing older eye cells with younger ones can help treat this disease. Objective To test the safety of …

detachment
drusen
age-related macular degeneration
eye exam
retinal pigment
  • 421 views
  • 15 Mar, 2021
  • 1 location